On August 13, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol INBS, issued a press release addressing the growing need for drug testing solutions in critical industries. The press release, now publicly available as Exhibit 99.1, was announced in a Form 8-K filing with the SEC. Intelligent Bio Solutions highlighted the increasing prevalence of drug use on the job in sectors such as construction, manufacturing, transportation, warehousing, mining, and automotive. The company cited various studies and surveys, including a 2023 SAMHSA national survey, indicating significant percentages of illicit drug use among full-time workers. The press release also mentioned the impact of prescription drug misuse on employers. Intelligent Bio Solutions emphasized its position as...Show More

On August 13, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated company listed on the Nasdaq Stock Market under the symbol INBS, issued a press release addressing the growing need for drug testing solutions in critical industries. The press release, now publicly available as Exhibit 99.1, was announced in a Form 8-K filing with the SEC. Intelligent Bio Solutions highlighted the increasing prevalence of drug use on the job in sectors such as construction, manufacturing, transportation, warehousing, mining, and automotive. The company cited various studies and surveys, including a 2023 SAMHSA national survey, indicating significant percentages of illicit drug use among full-time workers. The press release also mentioned the impact of prescription drug misuse on employers. Intelligent Bio Solutions emphasized its position as a leader in providing innovative, non-invasive drug testing technologies, specifically mentioning its Intelligent Fingerprinting Drug Screening System. The company plans to offer further insights in the weeks leading up to its Annual Report on Form 10-K and its upcoming earnings release. The press release also contained forward-looking statements regarding the company's development and commercialization prospects for its drug and diagnostic tests.